Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-12-03

Clinical Trial Update: Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of trametinib in patients with NF1-mutant non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Trametinib (trametinib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-12-03